嘌呤能受体X1与肺腺癌预后及免疫细胞浸润的相关性研究

doi:10.3969/j.issn.1004-616x.2022.05.004

Abstract

Abstract: OBJECTIVE: To explore the expression level of P2RX1 in non-small cell lung adenocarcinoma (LUAD) and to investigate relationships among P2RX1 expression,prognosis and tumor immune infiltration level of LUAD patients.METHODS: Different bioinformatic tools were used to explore correlations between P2RX1 expressions and DNA methylation levels in LUAD.The correlations between P2RX1 expression and prognosis of LUAD patients was also explored by different tools.The P2RX1 co-expressed genes were screened to explore the functional classifications and to select hub genes in LUAD.TIMER 2.0 database,R software and other bioinformatic tools were used to investigate correlations among P2RX1 expression,immune infiltration and immune checkpoints in LUAD.RESULTS: P2RX1 expressions were significantly downregulated in LUAD (P<0.05).Low P2RX1 expression levels tended to present worse prognosis in LUAD patients.In LUAD,P2RX1 expression was correlated with many clinicopathological factors such as tumor purity,stage and so on (P<0.05).No significant relationship was found between P2RX1 expression and prognosis of cancer.The methylation level of Cg06475633 was significantly associated with prognosis in LUAD patients.The P2RX1 coexpressed genes were mainly involved in immune cells activation,differentiation and other molecular biological process and signaling pathways.The selected hub genes contained BTK,IKZF1 and others.Most Hub genes were correlated with better prognosis in LUAD.The expression of P2RX1 was significantly correlated with immune cells infiltration especially with B cells infiltration in LUAD.P2RX1 expression was also positively correlated with immune stromal score,PD-1,CTLA-4 and many other immune checkpoints in LUAD (P< 0.05).CONCLUSION: P2RX1 might be useful as a biomarker for detection and as a therapeutic target for LUAD.

Key words: P2RX1, lung adenocarcinoma, database, prognosis

CLC Number:

R734.2

YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365.

References

[1] ZHANG W J. Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy[J]. Purinergic Signal, 2021, 17(1):151-162.
[2] WANG H W, WANG X R, XU L P, et al. High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma:a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets[J]. Purinergic Signal, 2020, 16(3):347-366.
[3] HUANG Z, LIU P, ZHU L, et al. P2X1-initiated p38 signalling enhances thromboxane A2-induced platelet secretion and aggregation[J]. Thromb Haemost, 2014, 112(1):142-150.
[4] LECUT C, FACCINETTO C, DELIERNEUX C, et al. ATPgated P2X1 ion channels protect against endotoxemia by dampening neutrophil activation[J]. J Thromb Haemost, 2012, 10(3):453-465.
[5] YANG X J, LU B, SUN X Q, et al. ANP32A regulates histone H3 acetylation and promotes leukemogenesis[J]. Leukemia, 2018, 32(7):1587-1597.
[6] WANG X, HU L P, QIN W T, et al. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis[J]. Nat Commun, 2021, 12:174.
[7] AUDRITO V. Pancreatic cancer immune evasion mechanisms:the immunosuppressive role of P2RX1-negative neutrophils[J]. Purinergic Signal, 2021, 17(2):173-174.
[8] AKHTARI M, ZARGAR S J, VOJDANIAN M, et al. P2 receptors mRNA expression profiles in macrophages from ankylosing spondylitis patients and healthy individuals[J]. Int J Rheum Dis, 2020, 23(3):350-357.
[9] WANG B H, LI Y Y, HAN J Z, et al. Gene methylation as a powerful biomarker for detection and screening of non-small cell lung cancer in blood[J]. Oncotarget, 2017, 8(19):31692-31704.
[10] YANG Y, LUO H, ZHENG X L, et al. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer:a systematic review and meta-analysis[J]. Clin Transl Oncol, 2021, 23(6):1117-1127.
[11] KUMAGAI S, TOGASHI Y, KAMADA T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies[J]. Nat Immunol, 2020, 21(11):1346-1358.
[12] CHERKASSKY L, MORELLO A, VILLENA-VARGAS J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition[J]. J Clin Invest, 2016, 126(8):3130-3144.
[13] DISKIN B, ADAM S, CASSINI M F, et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer[J]. Nat Immunol, 2020, 21(4):442-454.
[14] AHLUWALIA P, AHLUWALIA M, MONDAL A K, et al. Immunogenomic gene signature of cell-death associated genes with prognostic implications in lung cancer[J]. Cancers, 2021, 13(1):155.
[15] SUN S J, GUO W, WANG Z, et al. Development and validation of an immune-related prognostic signature in lung adenocarcinoma[J]. Cancer Med, 2020, 9(16):5960-5975.
[16] HAO D P, LIU J, CHEN M, et al. Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemosensitivity[J]. Clin Cancer Res, 2018, 24(15):3560-3571.

Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Yuling, LIU Ditian, CHEN Chunfa. Impact of CD68 macrophage infiltration on prognosis in primary small cell esophageal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 279-283.
[2]	WANG Xujuan, LUO Yongxin, LI Chenqiang, WANG Rujin, ZHENG Tingting. Predictive values of preoperative laboratory indices dNLR, SII and CRP/ALB on recurrences and metastases in breast cancer patient [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 284-288,323.
[3]	LIANG Feng, ZHANG Wei, LI Fei, WANG Shengjie, DU Yujing, ZHANG Yingchun. Expressions of lncRNA CASC9 in colorectal cancer and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 110-113.
[4]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[5]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[6]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[7]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[8]	ZENG Zhuoying, WU Desheng, LU Jingjing, LIAO Hui, LAI Hongpiao, YUAN Jianhui, HU Zhangli. Mediation by estrogen receptor α on oxidative phosphorylation pathways in development of lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 262-268.
[9]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[10]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[11]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[12]	WANG Yaokun, CHEN Juexiao, ZHANG Mingyuan, SHAO Changli, YANG Yu, SHANG Yu. Database analysis of genome variations and targeted drug screening of anaplastic thyroid cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 53-57.
[13]	SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443.
[14]	DU Qiang, YAO Yiyong, ZENG Gang. Expression and clinical significance of ASPM in lung adenocarcinoma according to the TCGA database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 457-463.
[15]	DING Yawen, JIAO Wenjing, WANG Pengyu, LU Gang, MA Ming. Immunophenotype characteristics of plasma cells and clinical significance in multiple myeloma patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 464-468,489.